Novartis AG 2016 AR2
The report outlines Novartis' performance in 2016, highlighting its organizational restructuring into a more integrated company with new Global Drug Development and manufacturing units. Despite facing generic competition for Gleevec, the company maintained net sales of USD 48.5 billion, driven by growth products like Cosentyx and Gilenya. In sustainability, Novartis reduced its carbon emissions by 10 kilotons and expanded its Novartis Access program to combat chronic diseases in lower-income countries, reaching over 120,000 treatments delivered. Additionally, the company ranked third in the Access to Medicine Index and achieved an A- rating in the CDP Climate Score.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2016
Type: AR2
Pages: 274
Novartis AG
The report outlines Novartis' performance in 2016, highlighting its organizational restructuring into a more integrated company with new Global Drug Development and manufacturing units. Despite facing generic competition for Gleevec, the company maintained net sales of USD 48.5 billion, driven by growth products like Cosentyx and Gilenya. In sustainability, Novartis reduced its carbon emissions by 10 kilotons and expanded its Novartis Access program to combat chronic diseases in lower-income countries, reaching over 120,000 treatments delivered. Additionally, the company ranked third in the Access to Medicine Index and achieved an A- rating in the CDP Climate Score.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees